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Background
The 2014 expert consensus on high dose interleukin-2
(HD-IL-2) states that, “Treating a minimum number of
patients per year is important, as quality depends upon
familiarity and repetition” [1]. The minimum annual
volume of HD-IL-2 associated with relatively worse out-
comes is not known.
Methods
We analyzed the National Inpatient Sample (NIS), one of
the largest publicly-available in-patient dataset in United
States (U.S.), which represents a 20% stratified random
sample of discharges from all hospitals. The NIS is drawn
from all States participating in Healthcare Cost and Utili-
zation Project, and thus represents 95 percent of the U.S.
population. Patients with melanoma and renal cell carci-
noma (RCC) were identified by using the ICD9 diagnostic
codes. From this sample, patients receiving HD-IL-2 were
identified by ICD9 procedure code 00.15. Annual hospital
volume was calculated using a unique hospital number,
available in the dataset. Using Joinpoint regression analy-
sis, which detects change in trend of in-patient mortality
with change in annual hospital volume, the hospitals were
classified in 3 volume categories (low, medium and high).
Multivariate logistic regression was used to identify predic-
tors of in-patient mortality controlling for confounders
including age, sex, Charlson comorbidity index, RCC,
calendar year, urban location and teaching status of
hospital.
Results
From 2003 to 2011, 29,532 patients (weighted number of
patients) with RCC or melanoma who received HD-IL-2
were identified, and 124 died during hospitalization, while
receiving HD-IL-2 (0.4%). Higher hospital volume was
associated with lower in-patient mortality (Figure 1). The
Joinpoint regression identified 3 categories of hospital by
annual hospital volume (low: 1-40 per year, medium:
41-120 per year, high >120 per year), which had significant
difference in in-patient mortality (0.83%, 0.29% and 0.13%
respectively, p=0.0003). On multivariate analysis, the low
volume hospitals were associated with higher odds of
in-patient mortality (OR 6.1, 95% CI 1.6-23.2, p=0.003) as
compared to high volume hospitals. Additionally, hospitals
with annual volume of 1-20 per year had even higher rates
of inpatient mortality (1.31% vs. 0.13%, p < 0.0001) and
multivariate odds (OR 8.9, 95% CI 2.4-33.2, p=0.0006) as
compared to high volume hospitals.
Conclusion
Lower annual hospital volume of HD-IL-2 is associated
with higher HD-IL2 related in-patient mortality. Annual
hospital volume of less than 20 treatments is associated
with 9 time higher risk of in-patient mortality as compared
to high volume hospitals.
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